| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 01/11/2007 | US20070010526 Therapeutic isoquinoline compounds |
| 01/11/2007 | US20070010517 Pharmaceutical salts of reboxetine |
| 01/11/2007 | US20070010457 Caspase inhibitors and uses thereof |
| 01/11/2007 | US20070010422 Improved bioavailability; for oral and intracolonic administration |
| 01/11/2007 | US20070010030 Complement C3 precursor biopolymer markers indicative of insulin resistance |
| 01/11/2007 | DE4342092B4 Langwirkende Injektionssuspension und Verfahren zur Herstellung Long-acting injection suspension and process for producing |
| 01/10/2007 | EP1741703A1 Pyridone derivative |
| 01/10/2007 | EP1741702A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof |
| 01/10/2007 | EP1741437A1 Functional food for ameliorating engogenous melatonin secretion rhythm and functional food for ameliorating circadian rhythm |
| 01/10/2007 | EP1740701A1 Osteogenic growth peptide fusion proteins |
| 01/10/2007 | EP1740213A2 Liquid growth hormone formulation |
| 01/10/2007 | EP1417227B1 Peptides eefective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/10/2007 | EP1414440B1 N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands |
| 01/10/2007 | EP1392320B1 17-METHYLENE-ANDROSTAN-3a-OL ANALOGS AS CRH INHIBITORS |
| 01/10/2007 | EP1313491B1 Bioactive fraction of eurycoma longifolia |
| 01/10/2007 | CN1893963A Production of hop extracts having oestrogenic and antiproliferative bioactivity |
| 01/10/2007 | CN1893955A Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
| 01/10/2007 | CN1891220A 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors |
| 01/10/2007 | CN1294142C 17 beta-carbothioate 17 alpha-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
| 01/10/2007 | CN1294141C 6 alpha., 9 alpha-difluoro-17.alpha.-[(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent |
| 01/10/2007 | CN1294134C Cyclohexylphenyl vasopression agonists |
| 01/09/2007 | US7160887 Aromatic amine derivatives, their production and use |
| 01/09/2007 | US7160558 Coating and binding agent for pharmaceutical formulations with improved storage stability |
| 01/09/2007 | CA2286190C Gnrh antagonists being modified in positions 5 and 6 |
| 01/09/2007 | CA2260145C Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1 |
| 01/04/2007 | WO2007000582A1 Heterocyclic non-peptide gnrh antagonists |
| 01/04/2007 | WO2005077968B1 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity |
| 01/04/2007 | US20070004703 Use of 1-(dialkoxyphenylsulfonyl)-3-(pyrrolidino)-3-(phenyl)indolin-2-one compounds to treat hypertension, cardiovascular disorders, central nervous system disorders, psychological disorders, gastrointestinal disorders; affinity for V1b and V1a receptors of arginine-vasopressin |
| 01/04/2007 | US20070004005 Tendon-inducing compositions |
| 01/04/2007 | US20070003946 Use of biomarkers in screening for insulin resistance |
| 01/04/2007 | US20070003556 Modified antibodies against cd22 and utilization thereof |
| 01/04/2007 | US20070003544 Combination therapy for treatment of autoimmune diseases using b- cell depleting/immunoregulatory antibody combination |
| 01/04/2007 | US20070003532 Novel mechanism for identifying drugs for the treatment of type II diabetes |
| 01/04/2007 | CA2613162A1 Heterocyclic non-peptide gnrh antagonists |
| 01/03/2007 | EP1739081A1 Hydrazino-substituted heterocyclic nitrile compounds and use thereof |
| 01/03/2007 | EP1738754A1 Solid pharmaceutical preparation |
| 01/03/2007 | EP1737880A1 17alpha-fluoro-17beta-hydroximinomethyl steroids, a method for production thereof and pharmaceutical compositions comprising said compounds |
| 01/03/2007 | EP1737813A1 Androgen modulators |
| 01/03/2007 | EP1633699B1 Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents |
| 01/03/2007 | EP1608360B1 Synergistic hepatoprotective composition and a method thereof |
| 01/03/2007 | EP1553938B1 Use of epothilone derivatives for the treatment of hyperparathyroidism |
| 01/03/2007 | EP1448221B1 Injection solution comprising an lhrh antagonist |
| 01/03/2007 | EP1423381B1 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 01/03/2007 | EP1390403B1 Peptides derived from neural thread proteins and their medical use |
| 01/03/2007 | EP1390040B1 Pharmaceutical composition for use in hormone replacement therapy |
| 01/03/2007 | EP1221865B1 Food supplement for increasing lean mass and strength |
| 01/03/2007 | EP1221439B1 Tetrahydroquinoline derivatives |
| 01/03/2007 | CN1890221A 1-N-phenyl-amino-1H-imidazole derivatives and pharmaceutical compositions containing them |
| 01/03/2007 | CN1293096C Method for synthesis of analogs of parathyroid hormone and parathyroid hormone related peptide |
| 01/03/2007 | CN1293090C 9-alpha-substituted estratrienes as selectively active estrogens |
| 01/03/2007 | CN1292796C Controlled release composition and method of producing the same |
| 01/02/2007 | US7157604 Selective estrogen receptor modulators |
| 01/02/2007 | US7157546 Water-soluble polymer alkanals |
| 01/02/2007 | US7157491 Hydroxy-phenyl)-aryl-carbaldehyde oxime derivatives; estrogen receptor modulators, treating inflammatory bowel diseases, Crohn's disease and colitis |
| 01/02/2007 | US7157479 Oxazol/thiazol-derivatives activators of the hPPAR-alpha receptor |
| 01/02/2007 | US7157469 For therapy of immune related responses, tumor growth, glomerulonephritis, inflammation, malarial anemia, septic shock, tumor associated angiogenesis, vitreoretinopathy, psoriasis, graft versus host disease, atopic dermatitis |
| 01/02/2007 | US7157451 Cardiac arrhythmias; potassium channel function inhibitors; such as 7-(3,4-Dichlorophenyl)-6-(5-fluoro-1-methyl-1H-benzimidazol-2-yl)-4,7 -dihydro-5-(methoxymethyl)pyrazolo-(1,5-a)pyrimidine |
| 01/02/2007 | US7157240 MID 4460, a human tyrosine phosphatase family member and uses therefor |
| 01/02/2007 | US7157099 Stable, biologically compatible pharmaceutical compositions in the form of water-in-oil microemulsions (w/o), for the sustained release by parenteral administration of active ingredients which are hydrophilic or are made hydrophilic by |
| 01/02/2007 | CA2436275C Polymeric delivery formulations of leuprolide with improved efficacy |
| 01/02/2007 | CA2400226C Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| 12/29/2006 | CA2551367A1 Multi-compartment delivery |
| 12/28/2006 | WO2006138715A1 Estrogen compositions for vaginal administration |
| 12/28/2006 | WO2006138686A1 Estrogen compositions for vaginal administration |
| 12/28/2006 | WO2006136461A2 Non-steroidal progesterone receptor modulators |
| 12/28/2006 | WO2006107273A8 Compounds having progestogenic activity and their use |
| 12/28/2006 | US20060293297 Cyanofluoropyrrolidine derviative |
| 12/28/2006 | US20060293247 Peptide derivatives; thyrotropin-releasing hormone-degrading; brain and spinal injuries, central nervous system disorders |
| 12/28/2006 | US20060292644 Novel tumor-associated marker |
| 12/28/2006 | US20060292131 Chondrocyte Therapeutic Delivery System |
| 12/28/2006 | DE10317528B4 Verfahren zur Herstellung von Calysteginen A process for preparing calystegines |
| 12/28/2006 | CA2612415A1 Estrogen compositions for vaginal administration |
| 12/28/2006 | CA2612380A1 Estrogen compositions for vaginal administration |
| 12/28/2006 | CA2611897A1 Non-steroidal progesterone receptor modulators |
| 12/28/2006 | CA2598216A1 Androgen receptor modulator compounds and methods |
| 12/27/2006 | EP1736470A2 Pyrimidine derivatives as CB2 cannabinoid receptor modulators |
| 12/27/2006 | EP1735331A1 D-homo-17-chloro-16(17)en steroids |
| 12/27/2006 | EP1734985A2 Methods for suppressing neovascularization using ephrinb2 |
| 12/27/2006 | EP1734920A2 Combination of a nmda receptor antagonist and an mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions |
| 12/27/2006 | EP1513861B1 New etonogestrel esters |
| 12/27/2006 | EP1448559B1 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thereof; and its use as pharmaceutical active ingredient |
| 12/27/2006 | EP1392276B1 Potentiation of therapeutic effects of polyunsaturated fatty acids |
| 12/27/2006 | EP1345895B1 Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
| 12/27/2006 | EP1332372B1 Net, a transcription factor of the tcf family, as regulator of angiogenic factor expression |
| 12/27/2006 | EP1299374B1 Novel non-psychotropic cannabinoids |
| 12/27/2006 | CN1886423A Glycoisoforms of adiponectin and uses thereof |
| 12/26/2006 | US7153997 N-hydroxyphenoxyphenyl derivatives of glycine or valine, e.g., N-[3,5-Dichloro-4-(4-hydroxy-3-isopropyl-5-methylphenoxy)benzoyl]glycine; treating metabolic disorders or diseases dependent upon the expression of a T3 regulated gene |
| 12/26/2006 | US7153951 A biologically active peptide at least 85% identical to a peptide: (a) X01ValSerGluX02GlnLeuX03HisX04X05GlyLysX06; (b) fragments containing amino acids 1-9, 1-10, 1-11, 1-12,(c) a salt or (d) N- or C- derivatives |
| 12/26/2006 | US7153881 Compounds acting as melanocortin receptor ligands |
| 12/26/2006 | US7153877 Chromium bound to niacin and three compounds from the group consisting of (-) hydroxycitric acid, zinc (particularly zinc methionine), trans-reseveratrol, gymnernic acid, selenium, an anthocyanidin, allicin, and fenugreek. |
| 12/26/2006 | US7153856 Orally administering N-(2-chloro-6-methylphenyl)-2-[4-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-6-ylamino]thiazole-5-carboxamide for treating cancer |
| 12/26/2006 | US7153825 Administering an exendin modified with a polyethylene glycol, gelatin and/or albumin to increase its biological half-life; treating hyperglucagonemia and diabetes, especially type II diabetes |
| 12/21/2006 | WO2006134167A1 Steroids having a mixed androgenic and progestagenic profile |
| 12/21/2006 | WO2006134148A2 Transglutaminase mediated conjugation of growth hormone |
| 12/21/2006 | WO2006133477A1 Peptides corresponding to human growth hormone |
| 12/21/2006 | US20060287374 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 12/21/2006 | US20060287349 Benzimidazolyl- or N-hetero analog derivatives of 4-aza-5 alpha -androstan-3-ones, e.g., beta -(1H-imidazo[4,5-c]pyridin-2-yl)-4-methyl-4-aza-5 alpha -androst-1-en-3-one; treatment of conditions caused by androgen deficiency |
| 12/21/2006 | US20060287348 N-(pyridin-2-ylmethyl)-4-methyl-3-oxo-4-aza-5 alpha -androst-1-en-17 beta -acetamide; enhancement of weakened muscle tone; osteoporosis, bone disorders; ; periodontal disease, frailty, aging skin, male hypogonadism, postmenopausal symptoms, inflammatory arthritis, cachexia, Alzheimer's disease |
| 12/21/2006 | US20060287340 e.g. 5-(4-fluorophenyl)-N-[2-(1-methyl-2-oxo-1,7-diazaspiro[4,4]nonan-7-yl)-6-quinolinyl]-2-pyrimidinecarboxamide; melanin concentrating hormone receptor antagonist; central nervous system disorders, cardiovascular disorders and metabolic disorders |
| 12/21/2006 | US20060287268 Splice-region antisense composition and method |